ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2019, Vol. 28 ›› Issue (3): 201-206.DOI: 10.3969/j.issn.1006-298X.2019.03.001

• 论文 •    下一篇

双重血浆置换治疗伴血栓性微血管病狼疮性肾炎的临床疗效

  

  • 出版日期:2019-06-28 发布日期:2019-07-23

Double filtration plasmapheresis treat  in lupus nephritis with thrombotic microangiopathy

  • Online:2019-06-28 Published:2019-07-23

摘要:

目的:观察双重滤过血浆置换(DFPP)联合免疫抑制剂治疗伴血栓性微血管病(TMA)狼疮性肾炎(LN)患者的临床疗效。
方法:30例伴TMA的LN患者(女性21例,男性9例),年龄264±108岁,系统性红斑狼疮疾病活动指数(SLEDAI)182±48分。均采用DFPP联合甲泼尼龙静脉治疗后续口服泼尼松联合免疫抑制剂治疗。观察DFPP治疗前后临床指标的变化[SLEDAI、血清肌酐(SCr)、免疫学指标和血管内皮指标等)],以及治疗3个月摆脱透析患者比例、肾脏缓解及存活情况。
结果:533%为初治患者,633%表现为急进性肾炎,SCr 3740±1830 μmol/L,567%的患者需要即时透析治疗。DFPP治疗(27±08次)后,SLEDAI和SCr明显下降,血清白蛋白上升,dsDNA转阴;6例血管性血友病因子裂解酶(ADAMTS13)活性降低的患者,经DFPP治疗后有4例ADAMTS13活性恢复正常,3例ADAMTS13抗体阳性的患者治疗后抗体均转阴;E选择素、血栓调节蛋白、循环内皮细胞(CECs)和血管内皮细胞黏附分子1(VCAM1)水平较治疗前均降低,除了CECs和VCAM1有显著差异外,其余无统计学差异。治疗3个月,肾脏及免疫学指标改善显著;17例需要肾脏替代治疗的患者中12例(706%)摆脱透析,18例(600%)患者治疗6个月获得缓解,10例发生肾脏终点事件。DFPP治疗不良事件少。
结论:DFPP联合免疫抑制治疗伴TMA的LN患者能快速降低疾病活动,改善血管内皮功能,临床缓解率和远期肾存活率较高。DFPP可作为伴TMA的LN患者一种有效治疗手段。

关键词: 重症狼疮性肾炎, 血栓性微血管病, 双重血浆置换, 内皮细胞功能, 临床疗效

Abstract:

Objective:To observation the clinical manifestations of lupus nephritis (LN) patients with thrombotic microangiopathy (TMA) and the efficacy of double filtration plasmapheresis (DFPP) therapy.
Methodology:Thirty active severe LN patients (average age 264±108 years) with TMA lesions were included.All patients were received DFPP and intravenous methylprednisolone pulse therapy,followed by oral glucocorticoids combined with immunosuppressants.The clinical manifestations and their changes of SLEDAI,SCr,indicators of immunology and endothelial function after DFPP therapy were observed.The ratio of patients free from dialysis at 3 months,remission rate and renal survival rate were analyzed.
Results:Amang 30  LN patients with TMA lesions,533% of them  were initial onset  and 633% patients showed rapidly progressive glomerulonephritis with SCr 3704±1830 μmol/L,567% of them need renal replacement therapy.After DFPP treatment (27±08),SLEDAI and SCr  decreased significantly,serum albumin increased and the titer of dsDNA decreased.
The ADAMTS13 activity were found decreased in 6 of 30 patients,and 4 of those patients returned to normal levels after therapy.3 patients with positive ADAMTS13 antibody at baseline changed to megative after treatment.
The levels of Eselectin,thrombomodulin,circulating endothelial cells (CECs) and vascular cell adhesion molecule 1 (VCAM1)  decreased after DFPP treatment,but there was no statistical difference except for CECs and VCAM1.The urinary and immunological indicators were also improved significantly at 3 months.12/17 (706%) patients who need renal replacement therapy at baseline were free from dialysis at 3 months.18 patients (600%) received response at 6 months.There were 10 patients occurred renal endpoint events.Few adverse events were found during DFPP treatment
Conclusion:DFPP combined with immunosuppressants can significantly decrease lupus activity and improve vascular endothelial dysfunction on LN patients with TMA lesions.The efficacy outcomes of DFPP  treatment  suggests DFPP is an alternative therapy for LN patients with TMA lesions.